

BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN: L24233MP1985PLC002709

Registered Office: B/12-B, Industrial Estate, Pologround, Indore-452015 (M.P.)

Tel. 0731-2426700; Email id- bcplcompliance@gmail.com;

Website- www.biofilgroup.net; Fax: 0731-2426700

Date: 30th May, 2026

To, The Secretary (DCS/Compliance), Corporate Relationship Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001	To, The Secretary (Listing/Compliance), Corporate Relationship Department, National Stock Exchange of India Limited , Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Mumbai – 400051
--	--

Subject: Outcome of Board Meeting held on Saturday 30th May, 2026 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Reference: Biofil Chemicals & Pharmaceuticals Limited (BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014)

Dear Sir/Madam,

With reference to the above captioned subject and pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors of the Company in their meeting (Serial No. 01/2026-2027) held on today i.e., Saturday, 30th Day of May, 2026, has inter alia, considered and approved the following businesses:

1. Audited Financial Results of the Company for the fourth quarter as well as financial year ended 31st March, 2026 along with Audit Report thereon, Statement of assets and liabilities and Cash Flow Statement.
2. Declaration regarding unmodified opinion of the Auditors on Annual Audited Financial Results of the Company pursuant to second proviso of Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015.
3. Other routine businesses with the permission of Chair.

Further, copy of aforesaid Audited Financial Results of the Company shall also be submitted in XBRL mode (Integrated Filing Financial) within prescribed time limit from conclusion of Board Meeting.

The aforesaid Audited Financial Results of the Company shall also be uploaded on the Company's website i.e. www.biofilgroup.net and on the website of the Stock Exchanges i.e. www.bseindia.com and www.nseindia.com. Further, publication containing a Quick Response code and the details of the webpage where complete financial results of the Company are available will be published in Hindi and English Newspapers within prescribed time limit.

The Meeting of the Board of Directors commenced at 04:30 P.M. and concluded at 05:30 P.M.

You are requested to please take on record the same.

Thanking you.

Yours Faithfully,

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

APOORV JAIN
COMPANY SECRETARY & COMPLIANCE OFFICER
M. NO. A71739

Enclosure: *Copy of Audited Financial Results along with the Auditors Report thereon, Statement of Assets and Liabilities and Cash Flow Statement for the fourth quarter and Financial Year ended 31st March, 2026.*

Independent Auditor's Report on the Statement of Audited Standalone Financial Results for the Quarter and Year ended March 31, 2026 of Biofil Chemical and Pharmaceuticals Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors
Biofil Chemicals and Pharmaceuticals Limited
Indore (M.P.)

Opinion

We have audited the accompanying quarterly and year to date standalone financial results of **M/s Biofil Chemicals and Pharmaceuticals Limited** ("The Company") for the quarter ended March 31, 2026 and year ended 31st March, 2026,, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, these quarterly financial results as well as the year to date results:

- i. are presented in accordance with the requirements of Listed Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the Accounting standards ("AS") and other accounting Principles generally accepted in India; of the net profit and other financial information for the Quarter and year ended 31st March 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Management's Responsibilities for the Standalone Financial Results

These standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Accounting Standard 25, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our



opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by SEBI under Regulation 33(B) of the Listing Regulations, to the extent applicable.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other Matter

- The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the third quarter current financial year, which were subject to a limited review by us, as required under the Listing Regulations.

For MAHESHWARI & GUPTA
Chartered Accountants
FRN: 006179C


CA. SUNIL MAHESHWARI
Partner
M. No. 403346



Place: Indore
Date: 30/05/2026
UDIN: 26403346OLILDL9191

Statement of Audited Financial Results for the Quarter and Year ended 31st March 2026


Sr No.	Particulars	Quarter Ended			Year Ended	
		March 31, 2026	December 31, 2025	March 31, 2025	March 31, 2026	March 31, 2025
		Audited	Un-Audited	Audited	Audited	Audited
I	Revenue from Operation	756.56	85.63	835.10	2839.52	3340.22
II	Other Income	10.85	7.83	23.67	308.23	30.52
III	Total Income	767.41	93.46	858.77	3147.75	3370.74
IV	Expenses					
	(a) Cost of materials consumed	179.84	323.15	207.56	738.32	531.46
	(b) Purchases of stock-in-trade	195.43	0.00	525.59	1876.95	2632.06
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	282.96	(288.03)	31.90	(19.19)	(78.91)
	(d) Employee benefits expense	22.00	19.13	24.89	79.98	78.50
	(e) Finance Cost	0.02	0.05	0.75	1.01	3.69
	(f) Depreciation and Amortisation Expense	7.41	6.60	8.34	27.20	37.96
	(g) Other expenses	32.87	21.89	34.36	98.52	92.37
	1. Manufacturing Expenses	5.59	7.38	15.34	32.61	46.46
	2. Administrative Expenses	25.49	14.22	20.88	60.87	41.55
	3. Selling and Distribution Expenses	1.79	0.29	(1.86)	5.04	4.35
	Total expenses	720.53	82.79	833.39	2802.79	3297.13
V	Profit/ (Loss) before exceptional items and tax	46.88	10.67	25.38	344.96	73.61
VI	Exceptional Items					
VII	Profit/ (Loss) before tax	46.88	10.67	25.38	344.96	73.61
VIII	Tax expense:					
	(1) Current tax	0.01	2.75	8.58	40.71	21.00
	(2) Deferred tax	25.65	0.00	(3.17)	25.65	(3.17)
	Total Tax expenses	25.66	2.75	5.42	66.36	17.83
IX	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00	0.00
X	Profit/(Loss) for the period from continuing operation	21.22	7.92	19.96	278.60	55.78
XI	Profit/(Loss) for the period for dis-continued operation	0.00	0.00	0.00	0.00	0.00
XII	Tax expenses of discontinued operation	0.00	0.00	0.00	0.00	0.00
XIII	Profit/(Loss) for the period for dis-continued operation after tax	0.00	0.00	0.00	0.00	0.00
XIV	Profit/ (Loss) for the period	21.22	7.92	19.96	278.60	55.78
XV	Other Comprehensive Income					
	A) (I) Items that will not be reclassified to Profit or Loss	(0.42)	0.00	2.80	(0.42)	2.80
	(II) Income Tax relating to items that will not be reclassified to Profit or Loss	0.10	0.00	(0.71)	0.10	(0.71)
	B) (i) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00
	(II) Income Tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00
XVI	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period)	20.90	7.92	22.06	278.27	57.87

XVII	Paid-Up equity share capital (face value of Rs 10/- each)	1627.38	1627.38	1627.38	1627.38	1627.38
XVIII	Reserves (Excluding Revaluation Reserve)				152.85	(125.42)
XIX	Earnings per equity shares (for continuing operation):					
	(1) Basic (Rs)	0.13	0.05	0.12	1.71	0.34
	(2) Diluted (Rs)	0.13	0.05	0.12	1.71	0.34
XX	Earnings Per Equity Share (for discontinued operation)					
	(1) Basic (Rs)	0.00	0.00	0.00	0.00	0.00
	(2) Diluted (Rs)	0.00	0.00	0.00	0.00	0.00
XXI	Earnings Per Equity Share (for continuing & discontinued operation)					
	(1) Basic (Rs)	0.13	0.05	0.12	1.71	0.34
	(2) Diluted (Rs)	0.13	0.05	0.12	1.71	0.34

- 1 The above Audited Financial Results for the Quarter and financial year ended March 31, 2026 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in it's meeting held on 30th May 2026. The above results have been audited by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
- 2 This statement has been prepared in accordance with the guidelines issued by the Securities and Exchange Board of India (SEBI) and the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- 3 The figures for the quarter ended 31st March 2026 and 31st March 2025 are the balancing figures between the audited figures in respect of the full financial year and the years to date figures up to the third quarter.
- 4 The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments
a. Pharma Division
b. Chemicals Division
- 5 Statutory Auditors of the Company has carried out audit of the books of accounts for the financial year 2025-2026 and issued us an Audit Report with unmodified opinion on Audited Financial Year for the quarter/year ended on 31st March, 2026, therefore the Company is not required to give statement of impact of Audit Qualification for Audit Report with modified opinion
- 6 The aforesaid audited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors. Further Publication containing a Quick Response Code and the details of the web page where complete financial results of the company are available will be published in english and hindi
- 7 The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.
- 8 The Statement of Assets & Liabilities as at March 31, 2026 is annexed with the results along with the Statement of Cash Flow.
- 9 The Net Profit of the company for the year ended 31st March, 2026 has been increased due to disposal of undertaking situated at 11/12, Sector E Sanwer Road Industrial Area, Indore M.P. To Formo Plast Private Limited after obtaining the approval of members of the company.
- 10 Due to the revision in Schedule M (Drug & Cosmetics Rules), the factory is presently undergoing renovation and upgradation work, therefore manufacturing operations were partially disrupted during the year, resulting in a decline in turnover as compared to previous year.

Date : 30/05/2026
Place Indore

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED



KETAN SHAH
CHAIRMAN AND MANAGING DIRECTOR
(DIN: 08818212)



BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN NO. L24233MP1985PLC002709

Regd Off: B/12-B, Industrial Estate, Pologround, Indore-452015 (M.P.)

Email Id:bcplcompliance@gmail.com Phone No. 0731-2426700, Website: www.biofilgroup.net

Audited statement of assets & liabilities as at 31-03-2026


(Amount in Lakhs)


Sr No.	Particulars	As at 31/03/2026	As at 31/03/2025
		Audited	Audited
A	ASSETS		
1	Non-current assets:		
	(a) Property, Plant & Equipment	693.50	834.48
	(b) Capital work in Progress		
	(c) Investment Property		
	(d) Goodwill		
	(e) Other Intangible assets		
	(f) Intangible Assets under development		
	(g) Biological Assets other than bearer plants		
	(h) Financial Assets:		
	i. Investments		
	ii. Trade receivables		
	iii. Loans		
	iv. Others (to be specified)		
	(i) Deferred tax assets (net)		
	(j) Other Non- Current Assets	5.03	6.21
	Security Deposit	5.03	6.21
	Sub-total - Non-current assets	698.53	840.68
2	Current assets		
	(a) Inventories	399.97	334.14
	(b) Financial Assets:		
	(i) Investment		
	(ii) Trade receivables	2,758.60	3,831.50
	(iii) Cash and cash equivalents	6.38	13.25
	(iv) Bank balances other than (iii) above	326.26	12.28
	(v) Loans		
	(vi) Others (to be specified)		
	(c) Current Tax Asset (Net)		
	(d) Other Currents Assets	95.05	64.19
	- Advance against material	42.60	34.81
	- Balance with Government authorities	49.65	24.27
	- Prepaid expenses	0.91	0.91
	- Other Assets	1.90	4.19
	Sub-total - Current assets	3,586.26	4,255.36
	TOTAL - ASSETS	4,284.81	5,096.04
B	EQUITY AND LIABILITIES		
1	Equity		
	(i) Equity Share Capital	1,627.38	1,627.38
	(ii) Other Equity	529.05	250.78
	Sub-total- Equity	2,156.43	1,878.16
2	Liabilities		
	Non-current Liabilities :		
	a. Financial Liabilities		
	(i) Borrowings		
	(ia) Lease Liabilities		
	(ii) Trade Payable		
	(a) total outstanding dues of micro enterprises and small enterprises; and		
	(b) total outstanding dues of creditors other than micro enterprises and small Enterprises.		
	(iii) other Financial Liabilities (other than those specified in item (b), to be specified)		
	b. Provisions		

	c. Deferred tax liabilities (net)	59.45	33.12
	d. Other Non-current Liabilities		
	Sub-total - Non-current liabilities	2,215.88	1,911.28
3	Current liabilities		
	a. Financial Liabilities		
	(i) Borrowings	302.00	47.13
	(ia) Lease Liabilities		
	(ii) Trade Payables :-		
	(a) total outstanding dues of micro enterprises and small enterprises; and		
	(b) total outstanding dues of creditors other than micro enterprises and small Enterprises.	1,706.04	3,098.78
	(iii) other Financial Liabilities [other than those specified in item (C)]		
	b. Other Current Liabilities	20.18	17.86
	- Employee benefits payable	3.65	3.18
	- Other Payable	16.53	10.26
	- Advance from Cutomers		4.41
	c. Provisions	40.71	21.00
	d. Current Tax Liabilities (Net)		
	Sub-total - Current liabilities	2,068.93	3,184.77
	TOTAL - EQUITY AND LIABILITIES	4,284.81	5,096.04

Date: 30-05-2026
Place: INDORE

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED


KETAN SHAH
CHAIRMAN AND MANAGING DIRECTOR
(DIN: 08818212)





BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN NO. L24233MP1985PLC002709

Regd Off: B/12-B, Industrial Estate, Pologround, Indore-452015 (M.P.)

Email Id:bcplcompliance@gmail.com Phone No. 0731-2426700, Website: www.biofilgroup.net

Statement of cash flows for the year ended 31st March 2026

(Amount in Lakhs)

Sr No.	Particulars	For the year	For the year
		ended March 31, 2026	ended March 31, 2025
		Audited	Audited
A)	Cash flow from operating activities		
	Profit before tax	344.96	73.62
	Adjustments to reconcile profit before tax to net cash used in operating activities	0.00	0.00
	Depreciation of property, plant and equipment	27.20	37.96
	Finance cost	1.01	3.69
	Impact of Gratuity considered in OCI	(0.31)	2.10
	Net (gain)/ loss on derivative contracts on account of Ind AS adjustments	372.86	117.36
	Provision for doubtful advances/debts		
	Working capital adjustments	0.00	0.00
	(Increase)/ Decrease in Inventory	(65.83)	(79.17)
	(Increase)/ Decrease in Trade Receivable, Current	1072.90	(528.59)
	(Increase)/ Decrease in Trade Receivable, Non Current	0.00	0.00
	(Increase)/ Decrease in other current assets	(30.87)	(9.66)
	(Increase)/ Decrease in other non current assets	1.18	(1.12)
	(Increase)/ Decrease in other financial assets, current	0.00	0.00
	(Increase)/ Decrease in other financial assets, non-current	0.00	0.00
	Increase/ (Decrease) in trade payables- Current	(1392.74)	343.29
	Increase/ (Decrease) in trade payables- Non-Current	0.00	0.00
	Increase/ (Decrease) in other financial liabilities- current	2.32	(11.21)
	Increase/ (Decrease) in other financial liabilities- Non-current	0.00	0.00
	Increase/ (Decrease) in other liabilities	46.05	(5.43)
	Cash generated from operations	5.87	(174.53)
	Tax Expenses		
	Current tax	(40.71)	(21.00)
	Deferred tax	(26.44)	3.13
	Adjustment of tax relating to earlier periods	0.79	0.04
	Net cash flows from operating activities (A)	(60.49)	(192.36)
B)	Cash flow from investing activities		
	Payment for purchase and construction of property, plant and equipment	(20.05)	(10.01)
	Proceeds from sale of property, plant and equipment	133.79	0.00
	(Increase)/ Decrease in other bank balances	0.00	0.00
	Interest received	0.00	0.00
	Net cash flows from investing activities (B)	113.74	(10.01)
C)	Cash flow from financing activities		
	Increase/(decrease) in Borrowings	254.87	3.24
	Deemed Investment by Holding Company	0.00	0.00
	Finance cost	(1.01)	(3.69)
	Net cash flows from financing activities (C)	253.86	(0.45)
	Net increase / (decrease) in cash and cash equivalents	307.11	(202.82)
	Cash and cash equivalents at the beginning of the year	25.53	228.35
	Cash and cash equivalents at the end of the year	332.64	25.53
	Increase / (Decrease) in cash and cash equivalents	307.11	(202.82)

Date: 30/05/2026
Place: INDORE

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

KETAN SHAH

CHAIRMAN AND MANAGING DIRECTOR
(DIN: 08818212)



Segmentwise Revenue, Results and Capital Employed for year ended 31st March 2026

(Amount in Lakhs)


S.No.	Particulars	Quarter Ended			Year Ended	
		March 31, 2026	December 31, 2025	March 31, 2025	March 31, 2026	March 31, 2025
		Audited	Un-Audited	Audited	Audited	Audited
1	Segment Revenue					
	Pharma Division	111.48	85.63	539.43	1,896.33	2,666.04
	Chemical Division	645.08	0.00	295.66	943.19	674.18
	Net sales/Income From Operations	756.56	85.63	835.10	2,839.52	3,340.22
2	Segment Results (Profit)(+)/ Loss (-) before tax and interest					
	Pharma Division	(30.63)	(10.45)	(6.99)	235.90	(14.38)
	Chemical Division	70.15	16.73	28.89	94.69	87.19
	Total Segment Profit Before Tax	39.52	6.28	21.90	330.59	72.81
	Interest Income	7.34	4.39	4.31	15.28	4.42
	Interest Expenses	(0.02)	0.01	0.83	0.91	3.61
	Other Unallocable Income net of Expenditure					
	Profit Before Tax	46.88	10.67	25.38	344.96	73.62
3	Capital Employed					
	Segment Assets (A)					
	Pharma Division	2,158.44	3,860.79	3,472.49	2,158.44	3,472.49
	Chemical Division	2,126.37	1,692.66	1,623.55	2,126.37	1,623.55
	Total (A)	4,284.81	5,553.45	5,096.04	4,284.81	5,096.04
	Segment Liabilities (B)					
	Pharma Division	1,270.47	3,162.57	2,919.95	1,270.47	2,919.95
	Chemical Division	857.91	255.35	297.93	857.91	297.93
	Total (B)	2,128.38	3,417.92	3,217.88	2,128.38	3,217.88
4	Total Capital Employed (Segment Assets-Segment Liabilities)					
	Pharma Division	887.97	698.22	552.54	887.97	552.54
	Chemical Division	1,268.46	1,437.31	1,325.62	1,268.46	1,325.62
	Total Capital Employed (Segment Assets-Segment Liabilities)	2,156.43	2,135.53	1,878.16	2,156.43	1,878.16

Date: 30-05-2026

Place: Indore

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED


KETAN SHAH
CHAIRMAN AND MANAGING DIRECTOR
(DIN: 08818212)



BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN: L24233MP1985PLC002709

Registered Office: B/12-B, Industrial Estate, Pologround, Indore-452015 (M.P.)

Tel. 0731-2426700; Email id- bcplcompliance@gmail.com;

Website- www.biofilgroup.net; Fax: 0731-2426700

Dated: 30th May, 2026

To,
The Secretary (DCS/Compliance),
Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-
400001

To,
The Secretary (Listing/Compliance),
National Stock Exchange of India Limited,
Exchange Plaza, C-1, Block G, Bandra Kurla
Complex, Mumbai - 400051

Subject: Submission of declaration regarding unmodified opinion of the Auditors on Annual Audited Financial Results of the Company for the year ended 31st March, 2026 as per second proviso to Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015.

REFERENCE: Biofil Chemicals and Pharmaceuticals Limited (BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014)

Dear Sir/Madam,

DECLARATION

Pursuant to Regulation 33(3)(d) of **SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**, as amended from time to time, the undersigned do hereby declare that in the Audit Report accompanying the Annual Financial Results of **BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED** for the financial year ended on **31st March, 2026**, the Statutory Auditor, Maheshwari & Gupta, Chartered Accountants (Indore), did not express any modified opinion/audit qualification or other reservation and accordingly, the Statement on Impact of Audit Qualifications is not required to be given.

Further, aforesaid declaration shall also be submitted in Integrated Filing- Financial XBRL within prescribed time limit.

You are requested to please consider and take on record the same.

Thanking You,

Yours faithfully

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

Ketan Shah (Chairman and Managing Director)
DIN: 08818212

Pawan Singh Rajput
CFO

Mrs. Gayatri Padiyar (Audit Committee Chairman)
DIN: 10260173

Maheshwari & Gupta (Auditor of the company)
Chartered Accountants
FRN: 006179C
CA Sunil Maheshwari
Partner
Membership number: 403346



